Evaluation of CA-125 and soluble CD-23 in patients with pelvic endometriosis: a case-control study

Ivana Maria de Luna Ramos, Sérgio Podgaec, Maurício Simões Abrão, Ricardo de Oliveira, Edmund Chada Baracat
Revista da Associacao Medica Brasileira (1992) · 2012 · vol. 58(1) , pp. 26–32 · doi:10.1590/s0104-42302012000100011 · PMID:22392313 · W2148171356
article OA: diamond CC0 ⤵ 15 in-corpus citations
🔓 Open OA copy Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

Serum CA-125 levels were elevated in endometriosis patients compared to controls and correlated with pain and disease stage, while soluble CD-23 showed no significant differences.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

To evaluate serum concentrations of CA-125 and soluble CD-23 and to correlate them with clinical symptoms, localization and stage of pelvic endometriosis and histological classification of the disease. Blood samples were collected from 44 women with endometriosis and 58 without endometriosis, during the first three days (1st sample) and during the 7th, 8th and 9th day (2nd sample) of the menstrual cycle. Measurements of CA-125 and soluble CD-23 were performed by ELISA. Mann-Whitney U test was used for age, pain evaluations (visual analog scale) and biomarkers concentrations. Serum levels of CA- 125 were higher in endometriosis patients when compared to the control group during both periods of the menstrual cycle evaluated in the study. This marker was also elevated in women with chronic pelvic pain, deep dyspareunia (2nd sample), dysmenorrhea (both samples) and painful defecation during the menstrual flow (2nd sample). CA-125 concentration was higher in advanced stages of the disease in both samples and also in women with ovarian endometrioma. Concerning CD-23, no statistically significant differences were observed between groups. The concentrations of CA-125 were higher in patients with endometriosis than in patients without the disease. No significantly differences were observed for soluble CD-23 levels between groups. Avaliar as concentrações séricas de CA-125 e CD-23 solúvel e correlacioná-los com sintomas clínicos, localização e estádio da endometriose pélvica e classificação histológica da doença. Amostras de sangue foram coletadas de 44 mulheres com endometriose e 58 sem endometriose durante os primeiros três dias (1ª amostra) e durante o sétimo, o oitavo e o nono dia (2ª amostra) do ciclo menstrual. As dosagens de CA-125 e CD-23 solúvel foram realizadas por ELISA. O teste U de Mann-Whitney foi usado para idade, avaliação de dor (escala analógica visual) e para a concentração dos biomarcadores. Os níveis séricos de CA-125 foram mais altos nas pacientes com endometriose do que no grupo-controle quando avaliados em ambos os períodos do ciclo menstrual, assim como apresentaram-se elevados nessas mulheres quando referiam dor pélvica crônica, dispareunia de profundidade (coleta na 2ª amostra), dismenorreia (ambas as amostras) e dor ao evacuar durante o fluxo menstrual (coleta na 2ª amostra). A concentração de CA-125 foi mais alta no estádio avançado em ambas as amostras, assim como em mulheres com endometriomas ovarianos. Em relação ao CD-23 solúvel, nenhuma diferença estatisticamente significativa foi observada entre os grupos. As concentrações de CA-125 foram mais altas em pacientes com endometriose do que em pacientes sem a doença. Nenhuma diferença estatisticamente significativa foi observada para CD-23 solúvel entre os grupos.
Full text 923 characters · extracted from preprint-html · click to expand
Redirecting var timerStart = Date.now(); var pageName = "Article Locator Bypass"; if (pageName == "") { pageName = "Auto Article Locator"; } function autoRedirectToURL() { var url = '/retrieve/'+document.getElementById('resultName').value+'?Redirect='+document.getElementById('redirectURL').value+'&key='+document.getElementById('key').value window.location = url; } siteCatalyst.pageDataLoad({ businessUnit : 'ELS:RP:ST', environment : 'prod', language : 'en', loadTime : (Date.now() - timerStart).toString(), loadTimestamp : Date.now().toString(), name : pageName, productName : 'IH', type : 'ih:article', detail : 'sciencedirect', format :"MIME-XHTML", accessType : 'ih:anon_guest', ipAddress : '102.211.204.30', identifierType : 'PII', identifierValue : 'S0104423012704657', articleName : 'Evaluation of CA-125 and soluble CD-23 in patients with pelvic endometriosis: a case-control study', location : "Linking Hub" });

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: preprint-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

mesh:D004412mesh:D004715mesh:D017699endometriosisendometriomachronic_pelvic_paindysmenorrheadyspareunia

MeSH descriptors

CA-125 Antigen Endometriosis Receptors, IgE Adolescent Adult Biomarkers Biomarkers CA-125 Antigen Case-Control Studies Dysmenorrhea Dysmenorrhea Endometriosis Endometriosis Female Humans Middle Aged Pelvic Pain Pelvic Pain Receptors, IgE Statistics, Nonparametric

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (24)

Cited by (15)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:16:17.081435+00:00
License: CC0 · commercial use OK